Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Vorinostat × Lymphoid × Clear all

Phase

Status

Completed 40 Terminated 14 Active not recruiting 5 Withdrawn 3 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 124 Rituximab 108 Vincristine 69 Etoposide 67 Doxorubicin 56 Cytarabine 56 Prednisone 51 Dexamethasone 51 fludarabine 45 Methotrexate 40 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 35 Lenalidomide 34 Gemcitabine 33 Radiotherapy 28 Melphalan 26 pegaspargase 21 Ifosfamide 21 Prednisolone 20 fludarabine phosphate 19 Busulfan 19 Bendamustine Hydrochloride 19 ibrutinib 16 Cisplatin 16 Asparaginase 16 Peripheral Blood Stem Cell Transplantation 15 Filgrastim 15 Carmustine 15 Oxaliplatin 14 Immunotherapy, Adoptive 14 Mercaptopurine 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02943642 2016-10-25

Resimmune®

Angimmune LLC

Phase 2 Unknown

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡